A patient with palmoplantar psoriasis who experienced secondary loss of response to brodalumab achieved disease control after switching to bimekizumab, according to a case report published in Cureus.

The report documents sequential biologic therapy within the IL-17 inhibitor class for palmoplantar disease, a presentation characterized by hyperkeratotic plaques, fissuring, and functional impairment on the palms and soles. Palmoplantar involvement commonly proves refractory to topical agents and conventional systemic therapies, and frequently responds less robustly than plaque disease at other body sites in pivotal biologic trials.

What does the case describe?

Authors writing in Cureus documented a single patient with palmoplantar psoriasis who initially responded to brodalumab, an IL-17 receptor A antagonist, then lost that response during maintenance therapy. The patient was subsequently treated with bimekizumab, a monoclonal antibody neutralizing both IL-17A and IL-17F, with reported clinical improvement.

The full outcome data — including Palmoplantar Psoriasis Area and Severity Index (ppPASI) scores, time to clinical response, and follow-up duration — are detailed in the original case report rather than the summary available here.

What is secondary loss of response?

Secondary loss of response describes initial clinical improvement followed by waning disease control during continued treatment. It occurs across biologic classes in moderate-to-severe psoriasis and has been reported with TNF inhibitors, IL-12/23 inhibitors, IL-23 inhibitors, and IL-17 pathway agents. Proposed mechanisms include antidrug antibody formation, pharmacokinetic variability, and disease-pathway redundancy.

When secondary failure develops within one biologic class, switching to an agent with a different molecular target represents standard practice. Switching within the same class — as in this report — remains less well characterized in published literature.

Why might a brodalumab-to-bimekizumab switch work?

Although both agents target the IL-17 axis, their mechanisms diverge. Brodalumab blocks the IL-17 receptor A subunit, inhibiting signaling from multiple IL-17 ligands. Bimekizumab neutralizes IL-17A and IL-17F directly while sparing IL-17C and IL-17E signaling. The mechanistic difference may preserve clinical efficacy when receptor blockade fails, a rationale the Cureus authors invoke explicitly.

Phase 3 trials have established bimekizumab's efficacy in moderate-to-severe plaque psoriasis, including head-to-head comparisons against adalimumab, secukinumab, and ustekinumab. Dedicated palmoplantar data, however, remain limited, leaving real-world and case-level evidence as the principal signal for this high-burden subtype.

How should clinicians interpret a single case report?

A case report ranks below controlled studies in the evidence hierarchy. It cannot establish response rates, durability, or generalizability. It can document therapeutic feasibility and generate hypotheses for larger studies.

The Cureus publication carries particular relevance for clinicians managing palmoplantar psoriasis refractory to first-line biologics. The case supplies documented bridge evidence between brodalumab's well-characterized limitations in some patients and bimekizumab's accumulating real-world record.

What safety considerations apply when sequencing these agents?

Safety profiles differ materially. Brodalumab carries a U.S. boxed warning regarding suicidal ideation and behavior, prompting Risk Evaluation and Mitigation Strategy (REMS) requirements at launch. Bimekizumab's label highlights oral candidiasis, injection-site reactions, and elevated hepatic transaminases in a minority of treated patients. Patient counseling should reflect both profiles when sequencing therapy, particularly in patients with prior mood disorders or recurrent fungal infections.

What comes next?

Registry data and pooled analyses of bimekizumab-treated patients with prior IL-17 receptor antagonist exposure would clarify whether the pattern observed in this case generalizes across broader populations. Until such data emerge, case-level documentation offers the most accessible signal for clinicians weighing intra-class switches after secondary biologic failure.

The case also raises a practical question for payers and formulary committees: whether step-edit policies requiring documented failure of one IL-17 agent before accessing another reflect emerging evidence on cross-agent efficacy, or persist from older treatment paradigms built around class homogeneity that no longer holds.

Dermatologists should treat the Cureus report as hypothesis-generating rather than practice-changing, awaiting broader evidence before formalizing brodalumab-to-bimekizumab sequencing in palmoplantar psoriasis protocols.